Infectious Disease Puscast· Folge 42
Infectious Disease Puscast #42
Dienstag, 28. November 2023 · 37 min
Kapitelklicken springt direkt hin
Shownotes
On episode #42 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 11/09 – 11/21/23.
Host: Daniel Griffin (parasiteswithoutborders.com) and Sara Dong
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of Puscast!
Links for this episode • Progress toward measles elimination (CDC)
• Slaying the troll of transplantation (TID)
• Association between the neutrophil-to-lymphocyte ratio and adverse outcomes in children aged • Pre-exposure prophylaxis use history in people with antiretroviral resistance at HIV diagnosis (CID)
• Impact of the 2019 FDA guidance for uncomplicated UTI on treatment response rates (OFID)
• CDC Guidelines for the prevention and treatment of anthrax (cdc.gov/mmwr/volumes/72/rr/rr7206a1.htm?s_cid=…) (CDC)
• Contemporary use of cefazolin for MSSA infective endocarditis (IJID)
• Is carbapenem therapy necessary for treatment of non-CTX-M ESBL-producing Enterobacterales bloodstream infections (CID)
• Infectious diseases consultation associated with reduced mortality in gram-negative Bacteremia (CID)
• Contemporary management of Staphylococcus aureus bacteremia (CID)
• Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal (Nature)
• Impact of in-house Candida auris PCR screening on admission on the incidence rates of surveillance and blood cultures with C. auris and associated cost savings (OFID)
• Human lobomycosis caused by Paracoccidioides loboi (EID)
• Molecular surveillance detects high prevalence of the neglected parasite Mansonella ozzardi (JID)
• Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults (The Lancet)
• Efficacy of bortezomib for treating anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency (AOID) syndrome (CID)
• Investigational non-antibiotic therapeutics for infections in hematopoietic cell transplant recipients and patients with hematologic malignancies receiving cellular therapies (TID)
• Black box warning: large language models and the future of infectious diseases consultations (CID)
Music is by Ronald Jenkees (ronaldjenkees.com)